The Risk Intelligent Life Sciences Company
Issue No. 4 in the Risk Intelligence Series
The life sciences industry (pharmaceuticals, biotechnology and medical devices) faces significant risks inherent in the business. Executives and directors must address the continual demands of a multitude of constituents — regulators, investors, partners, insurers, physicians, patients, lawyers, media and others. Meeting these needs adds complexity and heightens risk, and as these risks converge and overlap, management of them becomes simultaneously more difficult and more essential.
This paper — the fourth title in the Risk Intelligence Series — provides practical guidance and real-world examples of how to more effectively address the industry’s complex risk matrix, and cites a number of fundamental steps organizations need to undertake to create a Risk Intelligent Enterprise™.
To view the entire paper, download the document below.